Healthcare & Life Sciences: Drug Pricing Digest - May 2022

Eric Greig, Stuart Kurlander, Christopher Schott, Lee Staley
Latham & Watkins LLP
Contact
LinkedIn
Facebook
X
Send
Embed

Drug Pricing Initiatives: In advance of the midterm elections in November, discussion continues in Congress and among stakeholders of drug pricing reform measures, including those that were originally part of H.R. 5376 (the Build Back Better Act, or BBBA).

Please see full publication below for more information.

View PDF
Download PDF [291KB]
Email
Report

LOADING PDF: If there are any problems, click here to download the file.
Send Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations. Attorney Advertising.

© Latham & Watkins LLP

Written by:

Latham & Watkins LLP
Latham & Watkins LLP
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Latham & Watkins LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide